Sanofi India Limited Total Liabilities
Sanofi India Limited total liabilities. Based on the latest financial reports, Sanofi India Limited (SANOFI) has total liabilities worth Rs5.81 Billion INR (≈ $62.88 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SANOFI financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sanofi India Limited (2004–2025)
Total liabilities of Sanofi India Limited from 2004 to 2025. This chart illustrates how Sanofi India Limited's total liabilities have evolved over time, based on quarterly financial data. Explore SANOFI long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Sanofi India Limited Competitors by Total Liabilities
The table below lists competitors of Sanofi India Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yutong Optical
SHE:300790
|
China | CN¥3.30 Billion |
|
Clinica Baviera
MC:CBAV
|
Spain | €130.65 Million |
|
Sparekassen Sjaelland-Fyn A/S
CO:SPKSJF
|
Denmark | Dkr30.11 Billion |
|
SK Networks Co Ltd
KO:001740
|
Korea | ₩3.24 Trillion |
|
Corsair Gaming Inc
NASDAQ:CRSR
|
USA | $516.53 Million |
|
Silence Therapeutics PLC
NASDAQ:SLN
|
USA | $67.94 Million |
|
Clairvest Group Inc.
TO:CVG
|
Canada | CA$223.29 Million |
|
Radius Recycling, Inc.
NASDAQ:RDUS
|
USA | $944.09 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Sanofi India Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sanofi India Limited asset portfolio.
Liquidity & Leverage Metrics
Sanofi India Limited Total Liabilities Ratios Explained
Sanofi India Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sanofi India Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sanofi India Limited (2004–2025)
The table below shows the annual total liabilities of Sanofi India Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Rs5.06 Billion ≈ $54.68 Million |
-32.69% |
| 2024-12-31 | Rs7.51 Billion ≈ $81.24 Million |
+7.38% |
| 2023-12-31 | Rs7.00 Billion ≈ $75.66 Million |
-12.10% |
| 2022-12-31 | Rs7.96 Billion ≈ $86.07 Million |
-4.73% |
| 2021-12-31 | Rs8.35 Billion ≈ $90.35 Million |
+4.49% |
| 2020-12-31 | Rs8.00 Billion ≈ $86.46 Million |
-0.32% |
| 2019-12-31 | Rs8.02 Billion ≈ $86.74 Million |
+4.89% |
| 2018-12-31 | Rs7.65 Billion ≈ $82.70 Million |
+1.88% |
| 2017-12-31 | Rs7.51 Billion ≈ $81.17 Million |
-6.69% |
| 2016-12-31 | Rs8.04 Billion ≈ $86.99 Million |
+3.47% |
| 2015-12-31 | Rs7.77 Billion ≈ $84.08 Million |
+4.81% |
| 2014-12-31 | Rs7.42 Billion ≈ $80.22 Million |
+48.92% |
| 2013-12-31 | Rs4.98 Billion ≈ $53.87 Million |
+16.60% |
| 2012-12-31 | Rs4.27 Billion ≈ $46.20 Million |
+10.69% |
| 2011-12-31 | Rs3.86 Billion ≈ $41.74 Million |
-2.11% |
| 2010-12-31 | Rs3.94 Billion ≈ $42.64 Million |
+44.13% |
| 2009-12-31 | Rs2.74 Billion ≈ $29.58 Million |
+15.80% |
| 2008-12-31 | Rs2.36 Billion ≈ $25.55 Million |
+13.19% |
| 2007-12-31 | Rs2.09 Billion ≈ $22.57 Million |
-16.52% |
| 2006-12-31 | Rs2.50 Billion ≈ $27.04 Million |
+46.23% |
| 2005-12-31 | Rs1.71 Billion ≈ $18.49 Million |
+14.30% |
| 2004-12-31 | Rs1.50 Billion ≈ $16.18 Million |
-- |
About Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targoci… Read more